In work conducted at China Pharmaceutical University, synthesis and optimization of a new series of cyclin-dependent kinase 9 (CDK9) inhibitors bearing a flavonoid scaffold led to the identification of compound [I] as the lead candidate, with IC50 of 6.7 nM for CDK9 and >80-fold selectivity over CDK2 and most other CDK family members.
Prelude Therapeutics Inc. has described phosphatidylinositol 3-kinase α (PI3Kα) (His1047Arg mutant) inhibitors reported to be useful for the treatment of cancer and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities.
Nerviano Medical Sciences Srl has identified cyclin-dependent kinase 11A (CDK11A) inhibitors reported to be useful for the treatment of cancer and immunological disorders.
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have disclosed HER2 (erbB2) and/or HER2 (erbB2) mutant inhibitors reported to be useful for the treatment of cancer.
Chimeric Therapeutics Ltd. has received FDA clearance of its IND application for CHM-2101, a first-in-class CDH17 chimeric antigen receptor (CAR) T cell therapy for gastrointestinal (GI) cancers.
Sparx Biopharmaceutical Corp. has received FDA approval of its IND application for SPX-303, a first-in-class anti-LILRB2/PD-L1 bispecific antibody drug candidate.
Researchers from Biontech SE and Genmab BV presented the discovery and preclinical evaluation of a novel Duobody-EpCAMx4-1BB (BNT314/GEN1059), a novel Fc-inert immunomodulatory bispecific antibody (bsAb) designed to boost antitumor immune responses through EpCAM-dependent 4-1BB agonistic activity.
Researchers from Shanghai Henlius Biotech Inc. presented the discovery and preclinical characterization of HLX-42, a next-generation EGFR-targeting antibody-drug conjugate (ADC) being developed for the treatment of cancer.
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in a Shouyao Holdings (Beijing) Co. Ltd. patent to be useful for the treatment of cancer.
A team at Berrybio (Shanghai) Ltd. has prepared proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to focal adhesion kinase (FAK)-targeting moiety through a linker.
RSS
